Show simple item record

dc.contributor.authorMateo, Jen_US
dc.contributor.authorBoysen, Gen_US
dc.contributor.authorBarbieri, CEen_US
dc.contributor.authorBryant, HEen_US
dc.contributor.authorCastro, Een_US
dc.contributor.authorNelson, PSen_US
dc.contributor.authorOlmos, Den_US
dc.contributor.authorPritchard, CCen_US
dc.contributor.authorRubin, MAen_US
dc.contributor.authorde Bono, JSen_US
dc.date.accessioned2017-01-05T17:03:44Z
dc.date.issued2016-08-30en_US
dc.identifier.citationEuropean urology, 2016en_US
dc.identifier.issn0302-2838en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/377
dc.identifier.eissn1873-7560en_US
dc.identifier.doi10.1016/j.eururo.2016.08.037en_US
dc.description.abstractFor more precise, personalized care in prostate cancer (PC), a new classification based on molecular features relevant for prognostication and treatment stratification is needed. Genomic aberrations in the DNA damage repair pathway are common in PC, particularly in late-stage disease, and may be relevant for treatment stratification.To review current knowledge on the prevalence and clinical significance of aberrations in DNA repair genes in PC, particularly in metastatic disease.A literature search up to July 2016 was conducted, including clinical trials and preclinical basic research studies. Keywords included DNA repair, BRCA, ATM, CRPC, prostate cancer, PARP, platinum, predictive biomarkers, and hereditary cancer.We review how the DNA repair pathway is relevant to prostate carcinogenesis and progression. Data on how this may be relevant to hereditary cancer and genetic counseling are included, as well as data from clinical trials of PARP inhibitors and platinum therapeutics in PC.Relevant studies have identified genomic defects in DNA repair in PCs in 20-30% of advanced castration-resistant PC cases, a proportion of which are germline aberrations and heritable. Phase 1/2 clinical trial data, and other supporting clinical data, support the development of PARP inhibitors and DNA-damaging agents in this molecularly defined subgroup of PC following success in other cancer types. These studies may be an opportunity to improve patient care with personalized therapeutic strategies.Key literature on how genomic defects in the DNA damage repair pathway are relevant for prostate cancer biology and clinical management is reviewed. Potential implications for future changes in patient care are discussed.en_US
dc.formatPrint-Electronicen_US
dc.languageengen_US
dc.language.isoengen_US
dc.titleDNA Repair in Prostate Cancer: Biology and Clinical Implications.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-08-12en_US
rioxxterms.versionofrecord10.1016/j.eururo.2016.08.037en_US
rioxxterms.licenseref.startdate2016-08-30en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEuropean urologyen_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.embargo.termsNo embargoen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorDe Bono, Johannen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record